Search
Mipomersen
go.drugbank.com/drugs/DB05528ApprovedMipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. … It is marketed under the brand name Kynamro in the United States, and the FDA label includes a black box warning of hepatoxicity.
Categories: Compounds used in a research, industrial, or household setting, Apolipoprotein B-100 Synthesis InhibitorFelbamate
go.drugbank.com/drugs/DB00949ApprovedFelbamate is an anticonvulsant drug used in the treatment of epilepsy. In particular, in the adult patient population, it can be employed to treat partial seizures (with and without generalization). … Alternatively, it is used to treat partial and generalized seizures associated with Lennox-Gastaut syndrome in children. It has a weak inhibitory effect on GABA receptor binding sites.
Synonyms: Carbamic acid 3-carbamoyloxy-2-phenyl-propyl ester, 2-phenyl-1,3-propanediol dicarbamateCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersCetuximab sarotalocan
go.drugbank.com/drugs/DB19240InvestigationalCetuximab sarotalocan is under investigation in clinical trial NCT03769506 (ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy … ) for the treatment of Recurrent Head/Neck Cancer.
Grazoprevir
go.drugbank.com/drugs/DB11575ApprovedIn a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Grazoprevir as first line therapy … in combination with [DB11574] for genotypes 1a, 1b, and 4 of Hepatitis C [A19593].
Mixtures: ZEPATIER® TABLETAS RECUBIERTASCategories: Antivirals for treatment of HCV infections, P-glycoprotein substratesBrentuximab
go.drugbank.com/drugs/DB05471InvestigationalWe are collaborating with the National Cancer Institute (NCI) on three clinical trials of SGN-30 in combination with chemotherapy for the treatment of relapsed Hodgkin lymphoma, front-line ALCL and pediatric … SGN-30 has demonstrated objective antitumor responses as a single agent in phase II clinical trials.
Disopyramide
go.drugbank.com/drugs/DB00280ApprovedInvestigationalA class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar … It also possesses some anticholinergic and local anesthetic properties.
Categories: Antiarrhythmics, Class I, Antiarrhythmics, Class IaMF101
go.drugbank.com/drugs/DB05052InvestigationalMF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal women. … MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation
Apremilast
go.drugbank.com/drugs/DB05676ApprovedInvestigationalIt belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. … [L7501] In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and
Mixtures: OTEZLA 10 MG. 20 MG Y 30 MG, OTEZLA 10 MG. 20 MG Y 30 MGCategories: Cytochrome P-450 Substrates, P-glycoprotein substratesMagnesium silicate
go.drugbank.com/drugs/DB13249ApprovedWithdrawnMagnesium silicate is a compound of magnesium oxide and silicon. It is the magnesium salt of silicic acid containing an unspecified amount of water. … [T186] It is known as talc and it presents many uses in the cosmetic industry, food industry and pharmaceutical industry.
Vamorolone
go.drugbank.com/drugs/DB15114ApprovedInvestigational[L48671,L48676] In December 2023, it was approved in the EU for the treatment of patients ≥4 years of age.[L49505] … [L48676] Vamorolone was approved by the FDA in October 2023 for the management of DMD in patients ≥2 years of age.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers